Generic Name and Formulations:
Sucralfate 1g; scored tabs.
Indications for CARAFATE:
Short-term (up to 8 weeks) treatment of active duodenal ulcer. Maintenance of healed duodenal ulcers (tabs only).
Active: 1g 4 times daily on an empty stomach for 4–8 weeks. Maintenance: 1g 2 times daily.
Susp: administer by oral route only; do not give intravenously. Monitor for glycemia in diabetic patients. Chronic renal failure. Dialysis. Tabs: swallowing impairment (eg, recent or prolonged intubation, tracheostomy, history of aspiration, dysphagia, others). Pregnancy (Cat.B). Nursing mothers.
Avoid antacids within 30mins of dosing. May reduce absorption of tetracyclines, quinidine, levothyroxine, phenytoin, cimetidine, digoxin, ciprofloxacin, norfloxacin, ketoconazole, ranitidine, theophylline; dose concomitant drugs 2hrs before sucralfate. Additive aluminum load with aluminum-containing antacids. Monitor warfarin.
Endocrinology Advisor Articles
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- AAP Shares List of 5 Unnecessary Pediatric Tests and Procedures
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Statin Use for CVD Prevention Increases Diabetes Risk in Overweight Patients
- Optimal Timing of Gastric Bypass and Cholecystectomy When Both Procedures Clinically Indicated
- Does Asthma Contribute to Infertility?
- Short-Term Probiotics Increase Weight Loss in Overweight, Obesity